GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Standard BioTools Inc (NAS:LAB) » Definitions » Price-to-Tangible-Book
中文

Standard BioTools (Standard BioTools) Price-to-Tangible-Book : (As of Apr. 24, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Standard BioTools Price-to-Tangible-Book?

As of today (2024-04-24), Standard BioTools's share price is $2.42. Standard BioTools's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $-3.19. Hence, Standard BioTools's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Standard BioTools's Price-to-Tangible-Book or its related term are showing as below:

During the past 13 years, Standard BioTools's highest Price to Tangible Book Ratio was 696.00. The lowest was 696.00. And the median was 696.00.

LAB's Price-to-Tangible-Book is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.47
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Standard BioTools's share price is $2.42. Standard BioTools's Book Value per Sharefor the quarter that ended in Dec. 2023 was $-1.85. Hence, Standard BioTools's P/B Ratio of today is .


Standard BioTools Price-to-Tangible-Book Historical Data

The historical data trend for Standard BioTools's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Standard BioTools Price-to-Tangible-Book Chart

Standard BioTools Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 696.00 - - - -

Standard BioTools Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Standard BioTools's Price-to-Tangible-Book

For the Diagnostics & Research subindustry, Standard BioTools's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Standard BioTools's Price-to-Tangible-Book Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Standard BioTools's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Standard BioTools's Price-to-Tangible-Book falls into.



Standard BioTools Price-to-Tangible-Book Calculation

Standard BioTools's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=2.42/-3.188
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Standard BioTools Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Standard BioTools's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Standard BioTools (Standard BioTools) Business Description

Traded in Other Exchanges
Address
2 Tower Place, Suite 2000, South San Francisco, CA, USA, 94080
Standard BioTools Inc manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. The company's segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Executives
Martin D Madaus director 290 CONCORD ROAD, BILLERICA MA 01821
Jeffrey G. Black officer: SVP & Chief Financial Officer 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Eli Casdin director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Partners Master Fund, L.p. director, 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Casdin Partners Fo1-msv, Lp director C/O CASDIN PARTNERS GP, LLC, 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Private Growth Equity Fund Ii Gp, Llc director 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Gp, Llc director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Private Growth Equity Fund Ii, L.p. director 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Fenel M Eloi director C/O INTERLEUKIN GENETICS INC, 135 BEAVER STREET, WALTHAM MA 02452
Caligan Partners Lp 10 percent owner 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Frank Witney director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Jeremy Steven Davis officer: SVP Chief Commercial Officer C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, SUITE 2000, SOUTH SAN FRANCISCO CA 94080
Hanjoon Alex Kim officer: Chief Operating Officer C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, SUITE 2000, SOUTH SAN FRANCISCO CA 94080
Michael Egholm director, officer: President & CEO 1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110